NOTVQ Market Analysis

Fundamentals

Updated daily after market close
P/E ratioForward 3.72
EPS (TTM)$-2.480.0% YoY
Profit margin-17.1%HEALTHCARE
Market cap$390420Micro cap

Valuation

Forward P/E
3.72
PEG ratio
P/B
0.01
P/S (TTM)
0.00
EV/EBITDA
68.66

Profitability & growth

ROE (TTM)
-74.1%
Operating margin
-16.0%
Revenue growth YoY
-5.4%
Dividend yield
Beta
3.92
Last earnings
May 11, 2026 · Estimate $-0.64 · Reported $-0.94
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Inotiv, Inc.

Company profile

Inotiv, Inc. (NOTVQ) is a prominent preclinical contract research organization that provides essential drug development and safety assessment services tailored for the biotech and pharmaceutical industries. The company offers a diverse array of solutions, including nonclinical imaging, pharmacology, and toxicology, which are critical in advancing the development of innovative therapeutics. With a focus on leveraging cutting-edge technologies and a highly competent workforce, Inotiv effectively delivers actionable insights that accelerate drug discovery processes. Positioned strategically…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
2701 KENT AVENUE, WEST LAFAYETTE, IN
Fiscal year end
September
Latest quarter
Mar 31, 2026
Market cap$390420
Shares outstanding$35.2M
52W high$0.33
52W low$0.01

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer